CHALLENGING TRADITIONAL PARADIGMS

Reshaping the rules of global market access

Health technology assessment and pricing rules are shifting fast, but many still follow outdated approaches. That’s why we have created a series of podcasts and blogs to cut through the noise, spotlight emerging trends, and help you stay ready for what’s next. 

blog
Myth 1: Centralized EU HTA will never happen
This blog explores three widely held myths in health technology assessment (HTA), pricing, and market access. We examine how regulatory changes, evidence requirements, and evolving payer expectations are reshaping the global landscape for life sciences companies.
 
blog
Myth 2: Pricing in Germany is always transparent
This blog examines the myth that pharmaceutical pricing in Germany is always fully transparent. It explores recent legislative changes, including the Medical Research Act (MFG), and how new options like confidential pricing and updated guardrails are reshaping pricing strategies and negotiations.
 
Ready to navigate the new access landscape?
Talk to an expert about strategies that turn insight into impact, whether it’s HTA, pricing, or global access challenges.

Related solutions

Contact Us